10x Genomics $TXG Stock: CenterBook Partners LP Lowers Holdings

Posted by Geri Gentry on Nov 13th, 2026

CenterBook Partners LP reduced its position in shares of 10x Genomics (NASDAQ:TXG – Free Report) by 76.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,045 shares of the company’s stock after selling 16,192 shares during the period. CenterBook Partners LP’s holdings in 10x Genomics were worth $456,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Allegiance Financial Group Advisory Services LLC bought a new position in 10x Genomics in the third quarter valued at about $389,000. Calamos Wealth Management LLC bought a new position in 10x Genomics during the 3rd quarter worth $234,000. Calamos Advisors LLC bought a new stake in shares of 10x Genomics in the 3rd quarter valued at $2,541,000. MBA Advisors LLC acquired a new stake in 10x Genomics during the 3rd quarter worth about $277,000. Finally, Greenleaf Trust bought a new stake in 10x Genomics in the third quarter worth approximately $330,000. 84.68% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on TXG shares. Royal Bank Of Canada assumed coverage on shares of 10x Genomics in a research note on Tuesday, September 1st. They set a “sector perform” rating and a $70.00 target price on the stock. Piper Sandler lifted their price target on shares of 10x Genomics from $47.00 to $80.00 and gave the company a “neutral” rating in a research note on Monday, September 28th. Stifel Nicolaus upped their price objective on shares of 10x Genomics from $50.00 to $68.00 and gave the company a “buy” rating in a report on Friday, November 6th. Morgan Stanley upped their price objective on shares of 10x Genomics from $40.00 to $70.00 and gave the company an “equal weight” rating in a report on Monday, October 12th. Finally, Barclays reduced their target price on 10x Genomics from $110.00 to $70.00 and set an “overweight” rating for the company in a research note on Monday. Five equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $68.40.

View Our Latest Research Report on TXG

10x Genomics Stock Down 4.8%

NASDAQ TXG opened at $59.10 on Friday. 10x Genomics has a 52 week low of $15.12 and a 52 week high of $102.81. The business has a 50 day moving average price of $74.02 and a 200-day moving average price of $42.38. The company has a market cap of $7.70 billion, a price-to-earnings ratio of -113.65 and a beta of 2.03.

10x Genomics (NASDAQ:TXG – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.12. The business had revenue of $150.67 million during the quarter, compared to the consensus estimate of $147.96 million. 10x Genomics had a negative net margin of 10.84% and a negative return on equity of 8.19%. 10x Genomics’s revenue was up 1.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.22) EPS. On average, equities research analysts anticipate that 10x Genomics will post -0.74 earnings per share for the current year.

Insider Transactions at 10x Genomics

In other news, Director Shehnaaz Suliman sold 5,723 shares of the business’s stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $81.19, for a total transaction of $464,650.37. Following the completion of the sale, the director directly owned 23,792 shares of the company’s stock, valued at $1,931,672.48. The trade was a 19.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Adam Taich sold 46,388 shares of the business’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $64.57, for a total transaction of $2,995,273.16. Following the sale, the chief financial officer directly owned 316,344 shares of the company’s stock, valued at approximately $20,426,332.08. The trade was a 12.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 159,333 shares of company stock valued at $10,655,070. Corporate insiders own 8.84% of the company’s stock.

10x Genomics Company Profile

(Free Report)

10x Genomics, Inc. develops technology for studying biological systems at single-cell and spatial resolution. Its instruments, consumables and software help researchers analyze gene expression and other features of cells while preserving information about their location within tissue. The company’s product platforms include Chromium for single-cell analysis, Visium for spatial gene-expression analysis and Xenium for in situ analysis of gene activity within tissue samples. Its tools are used in areas such as immunology, neuroscience, cancer research and drug discovery.